In two identical RCTs (OPERA I and OPERA II), people affected by relapsing MS (R-MS; PP-MS excluded) with active disease (defined as the presence of relapses over the previous 2 years) were randomized, in a 1:1 ratio, to receive intravenous ocrelizumab at a dose of 600 mg every 24 weeks or subcutaneous IFN at a dose of 44 μg three times weekly for 96 weeks (59). The gene discussed is IFNA1; the disease is myeloid sarcoma.